Fc gamma RIIIA/CD16a Antibody (DMC219) - Chimeric
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-48293
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # DMC219
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
Fc gamma RIIIA/CD16a recombinant protein expressed in mammalian cells (Accession# P08637). The exact amino acid sequence is proprietary.
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Description
This product is shipped at ambient temperature. Store at -20C to -80C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80C (Avoid repeated freezing and thawing).
Applications for Fc gamma RIIIA/CD16a Antibody (DMC219) - Chimeric
Application
Recommended Usage
ELISA
1:5000-10000
Flow Cytometry
1:100
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified from cell culture supernatant
Reconstitution
.
Formulation
PBS, pH 7.4, 5-8% Trehalose
Preservative
Trehalose
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C in powder form. Store at -80C once reconstituted.
Background: Fc gamma RIIIA/CD16a
Activating NK cell receptor function has been harnessed for its potential in tumor immunotherapy (5). One immunotherapy strategy is using bi- and tri-specific NK cell engagers (BiKE and TriKE) to target the Fc gamma RIIIA/CD16a receptor with tumor-associated antigens to stimulate a cytotoxic response and mount an attack on tumor cells (5). CD16a is also capable of antibody dependent cellular cytotoxicity (ADCC) through recognition of antibodies bound to target cells (5-6). CD16-induced NK cell activation allows for NK co-receptor expression including stimulatory receptors like CD137 or inhibitory receptors like TIGIT and PD-1, which serve as additional regulatory checkpoints during ADCC (6). Therapeutic antibodies for cancer treatment like rituximab or trastuzumab can be recognized by Fc gamma RIIIA/CD16a to activate NK cell-mediated killing of tumor cells (5-6).
References
1. Fossati, G., Bucknall, R. C., & Edwards, S. W. (2001). Fcgamma receptors in autoimmune diseases. European Journal of Clinical Investigation, 31(9), 821-831. https://doi.org/10.1046/j.1365-2362.2001.00881.x
2. Patel, K. R., Roberts, J. T., & Barb, A. W. (2019). Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms. Frontiers in Immunology, 10, 223. https://doi.org/10.3389/fimmu.2019.00223
3. Moldovan, I., Galon, J., Maridonneau-Parini, I., Roman Roman, S., Mathiot, C., Fridman, W. H., & Sautes-Fridman, C. (1999). Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunology Letters, 68(1), 125-134. https://doi.org/10.1016/s0165-2478(99)00041-3
4. Uniprot (P08637)
5. Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L. (2021). NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 80, 100870. https://doi.org/10.1016/j.mam.2020.100870
6. Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., & Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 45, 73-81. https://doi.org/10.1016/j.coi.2017.01.003
Long Name
Fc gamma Receptor III A
Alternate Names
CD16a, FCGR3A, FcgRIIIA
Gene Symbol
FCGR3A
Additional Fc gamma RIIIA/CD16a Products
Product Documents for Fc gamma RIIIA/CD16a Antibody (DMC219) - Chimeric
Product Specific Notices for Fc gamma RIIIA/CD16a Antibody (DMC219) - Chimeric
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...